Developing Point-of-Care Testing (POCT) and Health-Monitoring Products into New Revenue Pillars
First written in FY2016. 12 of 13 entries say "Restated". Latest entry: 2026-05-11.
The whole theme swung hardest in 2025: 2 of 9 companies on the "Worse" side.
3 other companies' latest entry also says "Restated".
- 2026-05-11RestatedEarnings
「In addition to serving medical institutions, we also worked on the development and sale of self-monitoring products that can be used by general consumers.」
The company continues to pursue the development and sale of self-monitoring products for general consumers. - FY2026-H1RestatedAnnual report
「In addition to products for medical facilities, we worked to develop and sell self-monitoring products that can be used easily by general consumers.」
The company continues its policy of focusing on the development and sale of self-monitoring products for general consumers, in addition to products for medical facilities. - FY2025RestatedAnnual report
「In addition to products for medical facilities, we worked to develop and sell self-monitoring products that can be used easily by general consumers.」
The company continues its policy of creating new businesses through the development and sale of self-monitoring products for general consumers, in addition to products for medical facilities. - FY2024RestatedAnnual report
「We also aim to create new businesses through the development of new products. (Product development keywords include "home healthcare," "preventive medicine," "preemptive medicine" and "POCT (point-of-care testing)," among others.)」
The company continues its policy of developing new products and creating new businesses centered on home healthcare, preventive medicine, preemptive medicine and POCT. - FY2023RestatedAnnual report
「We also aim to create new businesses through the development of new products.」
The company has reaffirmed its policy of creating new businesses through new product development. The product categories are centered on home healthcare, preventive medicine, preemptive medicine and POCT. - FY2022RestatedAnnual report
「We aim to create new businesses through the development of new products. (Product development keywords include "home healthcare," "preventive medicine," "preemptive medicine" and "POCT (point-of-care testing)," among others.)」
The company has reaffirmed its policy of creating new businesses centered on POCT, home healthcare, preventive medicine and preemptive medicine. - FY2021RestatedAnnual report
「We aim to create new businesses through the development of new products. (Product development keywords include "home healthcare," "preventive medicine," "preemptive medicine" and "POCT (point-of-care testing)," among others.)」
The company continues to pursue a policy of creating new businesses centered on POCT, home healthcare, preventive medicine and preemptive medicine. - FY2020RestatedAnnual report
「We aim to create new businesses through the development of new products. (Product development keywords include "home healthcare," "preventive medicine," "preemptive medicine" and "POCT (point-of-care testing)," among others.)」
The company continues to pursue new product development and the creation of new businesses centered on POCT, home healthcare, preventive medicine and preemptive medicine. It has not stated that these have been established as a new earnings pillar. - FY2019RestatedAnnual report
「By improving our development capabilities, we aim to become a prominent company in the healthcare field, establish a third pillar following blood collection tube preparation equipment and specimen testing equipment, and achieve stable growth in niche markets.」
The company continues to pursue the goal of making healthcare its third pillar, but has not stated that the field has been established as a new pillar. - FY2018RestatedAnnual report
「By improving our development capabilities, we aim to become a prominent company in the healthcare field, establish a third pillar following blood collection tube preparation equipment and specimen testing equipment, and achieve stable growth in niche markets.」
The company has reiterated its goal of making healthcare its third earnings pillar. - FY2017RestatedAnnual report
「By improving our development capabilities, we aim to become a prominent company in the healthcare field, establish a third pillar following blood collection tube preparation equipment and specimen testing equipment, and achieve stable growth in niche markets.」
The company has clearly reiterated its goal of making healthcare a third pillar following blood collection tube preparation equipment and specimen testing equipment. - FY2017-Q2RestatedAnnual report
「For R&D of new products, we will develop products in the POCT (note) field, where demand is expected to grow, as well as products for monitoring individuals' daily health status so that they become aware of the need to improve their lifestyle-related diseases, in response to rising national medical costs resulting from the increase in lifestyle-related diseases. We will focus on R&D with the aim of making these products a new earnings pillar alongside our core blood collection tube preparation equipment.」
The company continues to pursue the goal of making POCT products and health-monitoring products new earnings pillars. - FY2016First statedAnnual report
「For R&D of new products, we will develop products in the POCT field, where demand is expected to grow, as well as products for monitoring individuals' daily health status so that they become aware of the need to improve their lifestyle, in response to rising national medical costs resulting from the increase in lifestyle-related diseases. We will focus on R&D with the aim of making these products a new earnings pillar alongside our core blood collection tube preparation equipment.」
The company has set the goal of making POCT products and products for monitoring daily health status earnings pillars alongside its core blood collection tube preparation equipment.